Prime

Type your tag names separated by a space and hit enter

Blood-based biomarkers for Parkinson's disease.

Abstract

There is a pressing need for biomarkers to diagnose Parkinson's disease (PD), assess disease severity, and prognosticate course. Various types of biologic specimens are potential candidates for identifying biomarkers--defined here as surrogate indicators of physiological or pathophysiological states--but blood has the advantage of being minimally invasive to obtain. There are, however, several challenges to identifying biomarkers in blood. Several candidate biomarkers identified in other diseases or in other types of biological fluids are being pursued as blood-based biomarkers in PD. In addition, unbiased discovery is underway using techniques including metabolomics, proteomics, and gene expression profiling. In this review, we summarize these techniques and discuss the challenges and successes of blood-based biomarker discovery in PD. Blood-based biomarkers that are discussed include α-synuclein, DJ-1, uric acid, epidermal growth factor, apolipoprotein-A1, and peripheral inflammatory markers.

Links

  • Publisher Full Text
  • Authors

    , ,

    Source

    Parkinsonism & related disorders 20 Suppl 1: 2014 Jan pg S99-103

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    24262199

    Citation

    TY - JOUR T1 - Blood-based biomarkers for Parkinson's disease. AU - Chahine,Lama M, AU - Stern,Matthew B, AU - Chen-Plotkin,Alice, PY - 2013/11/23/entrez PY - 2013/11/23/pubmed PY - 2013/11/23/medline KW - Blood-based biomarkers KW - Metabolomics KW - Parkinson's disease KW - Proteomics SP - S99 EP - 103 JF - Parkinsonism & related disorders JO - Parkinsonism Relat. Disord. VL - 20 Suppl 1 N2 - There is a pressing need for biomarkers to diagnose Parkinson's disease (PD), assess disease severity, and prognosticate course. Various types of biologic specimens are potential candidates for identifying biomarkers--defined here as surrogate indicators of physiological or pathophysiological states--but blood has the advantage of being minimally invasive to obtain. There are, however, several challenges to identifying biomarkers in blood. Several candidate biomarkers identified in other diseases or in other types of biological fluids are being pursued as blood-based biomarkers in PD. In addition, unbiased discovery is underway using techniques including metabolomics, proteomics, and gene expression profiling. In this review, we summarize these techniques and discuss the challenges and successes of blood-based biomarker discovery in PD. Blood-based biomarkers that are discussed include α-synuclein, DJ-1, uric acid, epidermal growth factor, apolipoprotein-A1, and peripheral inflammatory markers. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/24262199/full_citation L2 - http://linkinghub.elsevier.com/retrieve/pii/S1353-8020(13)70025-7 ER -